<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Asfotase alfa: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Asfotase alfa: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Asfotase alfa: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="105139" href="/d/html/105139.html" rel="external">see "Asfotase alfa: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="109307" href="/d/html/109307.html" rel="external">see "Asfotase alfa: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45653212"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Strensiq</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872051"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Strensiq</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F45497819"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Enzyme</li></ul></div>
<div class="block doa drugH1Div" id="F45741241"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="364b1c0a-4978-47b7-8862-f8448b051a8e">Juvenile-onset hypophosphatasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile-onset hypophosphatasia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Round patient weight to the nearest kg when determining dose. Injection-site reactions may limit the tolerability of the 6 times per week regimen. The FDA-approved dose is based primarily on studies in pediatric patients; additional studies in adult patients with pediatric-onset hypophosphatasia suggest the labeled dosing is appropriate in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576866','lexi-content-ref-32987199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576866','lexi-content-ref-32987199'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SubQ: </b>2 mg/kg 3 times weekly <b>or</b> 1 mg/kg 6 times weekly.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991924"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989180"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dop drugH1Div" id="F45642737"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="109307" href="/d/html/109307.html" rel="external">see "Asfotase alfa: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Round patient weight to the nearest kg when determining dose. Do not administer the 80 mg/0.8 mL concentration vial to pediatric patients weighing &lt;40 kg; exposure is less than what is achieved with lower concentration vials.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ad1e5a7-1b15-4b18-afad-4779d6a42754">Perinatal/infantile-onset hypophosphatasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perinatal/infantile-onset hypophosphatasia (HPP):</b> Infants, Children, and Adolescents: SubQ: 6 mg/kg/week administered as either 2 mg/kg/dose 3 times weekly or 1 mg/kg/dose 6 times weekly; may titrate due to lack of efficacy (eg, no improvement in respiratory status, growth, or radiographic findings) up to 9 mg/kg/week administered as 3 mg/kg/dose 3 times weekly; in clinical trials, dose increases were considered after at least 4 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Whyte.1','lexi-content-ref-Whyte.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Whyte.1','lexi-content-ref-Whyte.2'])">Ref</a></span>); maximum total weekly dose: 9 mg/kg/week. Injection-site reactions may limit the tolerability of the 6-times-per-week regimen.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="364b1c0a-4978-47b7-8862-f8448b051a8e">Juvenile-onset hypophosphatasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile-onset hypophosphatasia (HPP):</b> Children and Adolescents: SubQ: 6 mg/kg/week administered as either 2 mg/kg/dose 3 times weekly or 1 mg/kg/dose 6 times weekly. Injection-site reactions may limit the tolerability of the 6-times-per-week regimen.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51065033"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51065034"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F45591538"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (≤15%), injection site pruritus (juvenile-onset HPP: ≤35%; perinatal/infantile-onset HPP: ≤15%), papule of skin (injection site: ≤23%), rash at injection site (≤23%), urticaria at injection site (≤23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ectopic calcification (juvenile-onset HPP: 55% perinatal/infantile-onset HPP: 5%), lipodystrophy (juvenile-onset HPP: 70%; perinatal/infantile-onset HPP: 15% to 18%), lipohypertrophy (injection site: 5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≤15%), oral hypoesthesia (≤15%), vomiting (3% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (≤15%), hypersensitivity reaction (10% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immunogenicity (positive for antidrug antibodies: 89%; neutralizing: 57%; presence of antidrug antibodies resulted in reduced systemic exposure of asfotase alfa)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Atrophy at injection site (juvenile-onset HPP: 40%; perinatal/infantile-onset HPP: 6% to 15%), bleeding at injection site (≤23%), bruising at injection site (juvenile-onset HPP: 20%; perinatal/infantile-onset HPP: 9%), cellulitis at injection site (≤23%), erythema at injection site (juvenile-onset HPP: 75%; perinatal/infantile-onset HPP: 23% to 44%), hematoma at injection site (≤23%), hypertrophy at injection site (juvenile-onset HPP: 30%; perinatal/infantile-onset HPP: 8%), induration at injection site (8% to 15%), inflammation at injection site (≤23%), injection site nodule (juvenile-onset HPP: 10%; perinatal/infantile-onset HPP: 3%), injection site reaction (including calcification: ≤90%), injection site scarring (≤23%), itching at injection site (juvenile-onset HPP: ≤35%; perinatal/infantile-onset HPP: ≤15%), pain at injection site (juvenile-onset HPP: ≤40%; perinatal/infantile-onset HPP: ≤15%), residual mass at injection site (≤23%), skin discoloration at injection site (including hyperpigmentation and macules: Juvenile-onset HPP: ≤40%; perinatal/infantile-onset HPP: ≤17%), swelling at injection site (juvenile-onset HPP: 30%; perinatal/infantile-onset HPP: 12%), tenderness at injection site (juvenile-onset HPP: ≤40%; perinatal/infantile-onset HPP: ≤15%), warm sensation at injection site (≤23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (≤15%), headache (≤15%), irritability (≤15%), pain (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle rigidity (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia, pyridoxine deficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Chronic active hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Lipoatrophy at injection sit</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Calcific conjunctivitis, corneal changes (calcification)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Calcium nephrolithiasis</p></div>
<div class="block coi drugH1Div" id="F45497570"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to asfotase alfa or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F45642719"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation/immune-mediated effects: The presence of antibodies has been reported in 89% of treated patients in clinical trials; 57% of these patients showed the presence of neutralizing antibodies. Formation of anti-drug antibody results in a reduced systemic exposure of asfotase alfa and suggests possible immune-mediated effects resulting in disease progression (effect of antibody formation on long-term efficacy is unknown). Consider anti-asfotase alfa antibody testing in patients with progression of symptoms or worsening of disease associated laboratory and imagining biomarkers after a period of initial therapeutic response (contact Strensiq Medical Information at 1-888-765-4747 or <a class="__cf_email__" data-cfemail="e38e86878a8d858ca3828f869b8a8c8dcd808c8e" href="/cdn-cgi/l/email-protection">[email protected]</a>).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ectopic calcifications: Ectopic calcification of the eye, including the cornea and conjunctiva, and the kidneys (nephrocalcinosis, nephrolithiasis) have been reported; there is insufficient information to determine if these events were consistent with the disease (patients with hypophosphatasia are at increased risk for developing ectopic calcifications) or due to asfotase alfa. No visual changes or changes in renal function were reported resulting from the occurrence of ectopic calcifications. Eye exams and renal ultrasounds are recommended at baseline and periodically during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have been reported; symptoms consistent with anaphylaxis, including difficulty breathing, choking sensation, nausea, periorbital edema, and dizziness, have been reported. Reactions may occur within minutes after administration or in patients on treatment for &gt;1 year. Other hypersensitivity reactions (eg, vomiting, fever, headache, flushing, irritability, chills, skin erythema, rash, pruritus, oral hypoesthesia) have also been reported. If a severe hypersensitivity reaction occurs, discontinue treatment and initiate appropriate medical treatment. If the decision is made to re-administer, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipodystrophy: Localized lipodystrophy, including lipoatrophy and lipohypertrophy, has been reported at injection sites after several months. Ensure proper injection technique and rotate injection sites.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated alkaline phosphatase: High serum alkaline phosphatase (ALP) levels are expected and reflect circulating asfotase alfa; serum ALP measurements should not be used to make clinical decisions during asfotase alfa treatment.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878808"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Craniosynostosis associated with increased intracranial pressure in some cases and worsening of preexisting craniosynostosis has been reported in clinical trials in patients &lt;5 years of age; causality with asfotase alfa has not been established due to insufficient data; craniosynostosis is frequently reported (61.3%) in patient with hypophosphatasia as manifestation of the condition. Monitor (eg, fundoscopy) patients &lt;5 years of age periodically (Strensiq prescribing information [European Medicines Agency] 2015).</p></div>
<div class="block foc drugH1Div" id="F45653213"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Strensiq: 18 mg/0.45 mL (0.45 mL); 28 mg/0.7 mL (0.7 mL); 40 mg/mL (1 mL); 80 mg/0.8 mL (0.8 mL) [contains mouse (murine) and/or hamster protein]</p></div>
<div class="block geq drugH1Div" id="F45653211"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F45762888"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Strensiq Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg/0.45ml (per 0.45 mL): $1,544.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">28 mg/0.7 mL (per 0.7 mL): $2,402.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $3,432.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per 0.8 mL): $6,864.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872052"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Strensiq: 18 mg/0.45 mL (0.45 mL); 28 mg/0.7 mL (0.7 mL); 40 mg/mL (1 mL); 80 mg/0.8 mL (0.8 mL) [contains mouse (murine) and/or hamster protein]</p></div>
<div class="block adm drugH1Div" id="F45642741"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SubQ:</b> For subcutaneous administration only in the abdominal area, thigh, deltoid, or buttocks. Do not shake. Allow unopened vials to reach room temperature (~15 to 30 minutes) prior to administration; do not warm in microwave or hot water; administer within 3 hours upon removal from refrigerator. Rotate the injection sites to reduce the risk of lipodystrophy. Do <b>not</b> administer injections in areas that are reddened, inflamed, or swollen. Solution is clear, slightly opalescent or opalescent, colorless to slightly yellow; few small translucent or white particles may be present; discard vial(s) not consistent with this appearance. Administer with 1 mL syringe with <sup>1</sup>/<sub>2</sub> inch needle (25 to 29 gauge). Use of 2 different gauge needles is recommended; 25 gauge to withdraw medication from the vial and 29 gauge for administration. For doses &gt;1 mL, split the volume equally between 2 syringes, and administer 2 injections using separate injection sites.</p></div>
<div class="block admp drugH1Div" id="F52614629"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: For subcutaneous administration only in the abdominal area, thigh, deltoid, or buttocks. Do not shake. Allow unopened vials to reach room temperature (~15 to 30 minutes) prior to administration; do not warm in microwave or hot water; administer within 3 hours upon removal from refrigerator. Rotate the injection sites to reduce the risk of lipodystrophy. Do not administer injections in areas that are reddened, inflamed, or swollen. Solution is clear, slightly opalescent or opalescent, colorless to slightly yellow; few small translucent or white particles may be present; discard vial(s) not consistent with this appearance. Administer with 1 mL syringe with <sup>1</sup>/<sub>2</sub>-inch needle (25 to 29 gauge). For doses &gt;1 mL, split the volume equally between 2 syringes, and administer 2 injections using separate injection sites.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In pediatric patients &lt;40 kg, do not use the 80 mg/0.8 mL vial; systemic exposure of asfotase alfa achieved with this higher concentration (80 mg/0.8 mL) is lower than that achieved with the other vial strengths which have a lower concentration. A lower exposure may not be adequate for this subgroup of patients.</p></div>
<div class="block use drugH1Div" id="F45497569"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Hypophosphatasia:</b> Treatment of perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)</p></div>
<div class="block cyt drugH1Div" id="F45525226"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45525223"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F45642684"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F45642685"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if asfotase alfa is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure, the benefits of breast-feeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F45642743"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reaction; signs and symptoms of ophthalmic and renal ectopic calcifications and for changes in vision or renal function; serum calcium, PTH, serum phosphate, 25-hydroxyvitamin D; periodic evaluations for craniosynostosis (including fundoscopy) in patients &lt;5 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional recommended patient assessments are based on patient age and include monitoring of biochemistry, skeletal radiographs, respiratory function, growth, pain, mobility and motor function, and quality of life (Kishnani 2017).</p></div>
<div class="block pha drugH1Div" id="F45642722"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Asfotase alfa is a human recombinant tissue-nonspecific alkaline phosphatase-Fc-deca-aspartate fusion protein with enzymatic activity that promotes bone mineralization in patients with hypophosphatasia.</p></div>
<div class="block phk drugH1Div" id="F45642724"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Reduction in plasma tissue-nonspecific alkaline phosphatase (TNSALP): After 6 to 12 weeks of treatment</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Age range: 1 day to 66 years:  Subcutaneous: 60.2%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~5 days (based on data from 38 patients, ages undefined); in 60 patients aged 1 day to 66 years (n=45 pediatric patients):  ~2.3 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak serum concentration:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤5 years: ~15 hours (range: 0 to 32.2 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt; 5 to 12 years:  ~ 21 hours (range: 12 to 32.2 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45524837"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Strensig | Strensiq</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Strensiq</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30576866">
<a name="30576866"></a>Kishnani PS, Rockman-Greenberg C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. <i>Bone</i>. 2019;121:149-162. doi:10.1016/j.bone.2018.12.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/asfotase-alfa-drug-information/abstract-text/30576866/pubmed" id="30576866" target="_blank">30576866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888853">
<a name="28888853"></a>Kishnani PS, Rush ET, Arundel P, et al. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.<i> Mol Genet Metab</i>. 2017;122(1-2):4-17. doi:10.1016/j.ymgme.2017.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/asfotase-alfa-drug-information/abstract-text/28888853/pubmed" id="28888853" target="_blank">28888853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32987199">
<a name="32987199"></a>Seefried L, Kishnani PS, Moseley S, et al. Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. <i>Bone</i>. 2021;142:115664. doi:10.1016/j.bone.2020.115664<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/asfotase-alfa-drug-information/abstract-text/32987199/pubmed" id="32987199" target="_blank">32987199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strensiq.1">
<a name="Strensiq.1"></a>Strensiq (asfotase alfa) [prescribing information]. Boston, MA: Alexion Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference">
                  Strensiq (asfotase alfa) [product monograph]. Zurich, Switzerland: Alexion Pharma GmbH; August 2021.</div>
</li>
<li>
<div class="reference">
                  Strensiq European (asfotase alfa) [prescribing information]. Dublin, Ireland: Alexion Pharma International Trading; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Whyte.1">
<a name="Whyte.1"></a>Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. <i>N Engl J Med</i>. 2012; 366(10):904-913.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Whyte.2">
<a name="Whyte.2"></a>Whyte MP, Rockman-Greenberg C, Ozono K, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. <i>J Clin Endocrinol Metab</i>. 2016;101(1):334-342.</div>
</li></ol></div><div id="topicVersionRevision">Topic 104963 Version 81.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
